Free Daily Podcast Summary
The ReProgram: Daily Summaries Delivered
by Dr. George Murphy
The ReProgram is dedicated to exploring how we can extend the healthy human lifespan through science and self-understanding. Hosted by Dr. George Murphy, each episode dives into the rapidly evolving fields of aging biology, longevity, regenerative medicine, and geroscience.From cellular rejuvenation and advanced therapeutics to lifestyle strategies that build resilience against disease, we examine what the science actually shows—and what it doesn’t. No hype. No myths. Just rigorous, evidence-based conversations about how we can reprogram our biology to live longer and healthier lives.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 1 weeks ago15 min
The ReProgram Scorecard: Metformin and Longevity
🧠 Episode OverviewMetformin is inexpensive, widely prescribed, and supported by decades of clinical experience. It is also one of the most frequently discussed drugs in longevity medicine.But does metformin actually slow human aging?In this episode, Dr. George Murphy puts metformin through The ReProgram Scorecard, examining its biological mechanisms, human evidence, safety, accessibility, and likely value for people with—and without—metabolic disease.The central distinction is context. Metformin can delay diabetes in people at elevated metabolic risk, but evidence that it extends lifespan or broadly prevents age-related disease in metabolically healthy adults remains limited.Final ReProgram Grade: B−For healthy-adult longevity use: C+🔑 KeywordsMetformin, metformin and longevity, biological aging, healthspan, diabetes prevention, insulin resistance, prediabetes, anti-aging drugs, longevity medicine, ReProgram Scorecard, Dr. George Murphy🧠 Key Takeaways• Metformin is an established metabolic drug, not a proven anti-aging medication.• Its mechanisms intersect with energy sensing, glucose regulation, inflammation, mitochondrial biology, AMPK, and mTOR.• The strongest benefits are seen in people with diabetes, prediabetes, insulin resistance, or elevated metabolic risk.• Evidence that healthy, insulin-sensitive adults benefit from taking metformin for longevity is weak.• Long-term follow-up found that metformin prevented diabetes but did not significantly reduce all-cause, cardiovascular, or cancer mortality.• The key question is not whether metformin affects aging-related pathways. It is whether it improves meaningful outcomes in the right population.🎙️ The ReProgram PerspectiveMechanism over marketing.Evidence over anecdotes.Trade-offs over hype.Metformin deserves respect as a safe, inexpensive, and valuable metabolic medicine.But correcting abnormal metabolism is not necessarily the same as slowing aging in someone whose metabolism is already healthy.The stronger the underlying metabolic dysfunction, the greater the potential benefit. For healthy adults seeking a general longevity drug, the evidence is not yet compelling.📊 The ReProgram ScorecardMechanistic plausibility: 4 / 5Human longevity evidence: 2.5 / 5Likely benefit — metabolic-risk populations: 4 / 5Likely benefit — metabolically healthy adults: 1.5 / 5Safety and downside risk: 4 / 5Cost and accessibility: 5 / 5Longevity hype risk: Moderate–HighHealthy-adult longevity use: C+Final ReProgram Grade: B−Verdict: An excellent metabolic drug and plausible geroscience tool—but not a proven longevity drug for healthy people.Chapters00:26 What Metformin Does 00:54 Is Metformin Really a Longevity Drug?02:37 Understanding Metformin: Mechanisms and Uses04:48 Evaluating Human Evidence for Metformin07:46 Magnitude of Likely Benefits of Metformin08:55 Safety and Potential Downsides of Metformin10:54 Who May Benefit Most from Metformin12:28 Cost, Accessibility, and Longevity Hype Risk13:42 Final ReProgram Grade📝 Notes and References1. Diabetes Prevention Program Research Group. Reduction in the Incidence of Type 2 Diabetes With Lifestyle Intervention or Metformin. New England Journal of Medicine. 2002;346:393–403. Metformin reduced diabetes incidence by 31%, compared with 58% for intensive lifestyle intervention. PubMed: <a href="https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbGpVbXRrWk9iRHByYzV0ZDhhZ3NWczFVdl9Gd3xBQ3Jtc0tuN1ppOVp6Q2FjV2Z3TW9FckRsRnpPSVlVYnVGWVJqeHludGdPeVozS19TY2RoT0I5T3RpRC1NUmU5bnQ1dUhfVWdYYlNP
- 2 weeks ago27 min
Dr. Raghav Sehgal: Can We Measure How Fast You Are Aging?
🧠 Episode OverviewWhat if your age on paper is not the number that matters most?In this episode of The ReProgram, Dr. George Murphy sits down with Dr. Raghav Sehgal at the Gordon Research Conference Systems Aging Meeting in Maine.Dr. Sehgal discusses his work analyzing dozens of putative longevity interventions across epigenetic clocks, why DNA methylation data are uniquely useful for cross-study harmonization, and why some interventions may move aging biomarkers only in specific biological contexts.The central message: aging clocks are not magic answers, but they may become powerful instruments for separating longevity science from longevity marketing.🔑 KeywordsRaghav Sehgal, biological age, chronological age, aging clocks, epigenetic clocks, biomarkers of aging, longevity interventions, geroscience, AI and aging, artificial intelligence, rapamycin, metformin, hronic inflammation, lifestyle interventions, exercise, diet, supplements, follistatin gene therapy, clinical translation, precision longevity, ReProgram Podcast, Dr. George Murphy🧠 Takeaways• Chronological age tells us how long we have been alive; biological age attempts to measure how fast health risk and physiological decline are progressing.• If aging cannot be quantified, it becomes difficult to test whether an intervention is actually modifying aging biology.• Epigenetic clocks are especially useful for large cross-study analyses because DNA methylation platforms are relatively standardized compared with many other omics technologies.• Dr. Sehgal describes a major harmonization effort across clinical trials and observational studies to ask which interventions move aging biomarkers.• Some surprising signals came from anti-retroviral therapy and inflammation-targeting drugs, raising questions about retrotransposons, immune activation, and chronic inflammation in aging.• Context matters: an intervention may shift aging biomarkers in one group, disease state, tissue, or organ system but not another.• Rapamycin remains promising in model organisms, but the human biomarker evidence is still more complicated and less definitive than the hype suggests.• AI may accelerate longevity science by cleaning messy datasets, mapping aging trajectories, and helping explain why a biological age score moved.• The future of longevity medicine will depend on better biomarkers, longitudinal data, careful interpretation, and avoiding one-size-fits-all claims.🎙️ The ReProgram PerspectiveThis episode is a reminder that longevity science is entering a measurement era. The key question is no longer only whether an intervention sounds plausible, works in mice, or has a compelling mechanism. The harder question is whether it measurably changes human aging biology in the right person, tissue, and context.The most important idea from this conversation may be that biological age is not a single magic number. It is a window into complexity. The promise of the field is not just to tell someone they are “younger” or “older” than expected. The promise is to understand why that signal is changing and what, if anything, can be done about it.Chapters02:33 Introduction from the Systems Aging GRC03:02 Biological Age vs Chronological Age04:28 Testing 51 Longevity Interventions06:20 Why Epigenetic Clocks?08:12 Anti-Retroviral Therapy, Retrotransposons, and Aging10:36 The Role of Inflammation in Aging12:23 What Counts as a True Longevity Signature?15:08 Rapamycin, Humans, and the Evidence Gap16:31 Surprising Findings From the Study18:19 Aging Clocks in the Clinic19:47 AI, Big Data, and Longevity Science22:32 Raghav’s Personal Health TransformationNotesDr. Sehgal's Website: https://www.raghav-sehgal.com/Dr. Sehgal's 51 Interventions Paper: https://www.biorxiv.org/content/10.1101/2024.10.22.619522v1.fullTranslAGE: https://www.translage.io/
- 3 weeks ago13 min
Dr. Mimi Shirasu-Hiza: Can Meal Timing Slow Aging?
🧠 Episode OverviewWhat if aging is shaped not only by what you eat, how much you exercise, or which genes you inherit — but also by when your body does things each day?In this episode of The ReProgram, Dr. George Murphy sits down with Dr. Mimi Shirasu-Hiza at the Gordon Research Conference Systems Aging Meeting in Maine.Dr. Shirasu-Hiza is a Professor of Genetics and Development at Columbia University and an international expert in circadian gene regulation, aging, and health.This conversation explores circadian rhythms as daily, approximately 24-hour oscillations in gene expression, tissue function, and behavior — and why disruption of those rhythms through shift work, jet lag, irregular sleep, or mistimed eating may affect metabolism, cardiovascular risk, obesity, cancer risk, and aging biology.A major focus is time-restricted eating: not simply eating less, but aligning eating and fasting with the body’s active and resting phases. Dr. Shirasu-Hiza discusses work in fruit flies showing that time-restricted eating can extend lifespan and preserve youthful oscillations in genes involved in metabolism, protein translation, immune defense, stress response, and other core biological programs.🔑 KeywordsCircadian rhythms, circadian clock, biological rhythms, time-restricted eating, intermittent fasting, caloric restriction, meal timing, fasting window, overnight fasting, metabolism, cardiovascular disease, obesity, cancer risk, aging biology, longevity science, geroscience, exercise, healthspan, resilience, ReProgram Podcast, Dr. George Murphy🧠 Takeaways• Circadian rhythms are daily, approximately 24-hour oscillations in gene expression, tissue function, and behavior.• The circadian clock is not just about sleep; it helps coordinate transcription, metabolism, feeding, fasting, activity, tissue function, and recovery.• Circadian disruption is associated with cardiometabolic disease, obesity, and cancer risk, especially in shift workers, frequent travelers, and others whose activity occurs during the usual rest phase.• Time-restricted eating is different from caloric restriction. It focuses on when food is consumed, not necessarily how many calories are consumed.• Aging may involve loss of rhythmic gene expression. Time-restricted eating preserved youthful oscillations in genes linked to metabolism, protein translation, immune defense, defense response, and stress response.• Meal timing may help reset circadian rhythms during jet lag, suggesting that food can act as a timing cue for the body clock.🎙️ The ReProgram PerspectiveThis episode is a reminder that longevity science is not only about molecules, supplements, or single interventions. It is also about biological organization.Circadian biology reframes aging as a problem of timing. Genes, metabolism, immunity, tissue repair, behavior, feeding, and fasting are not static processes. They are coordinated across the day.Dr. Shirasu-Hiza’s work in flies is powerful because it shows that preserving youthful gene-expression rhythms may be linked to lifespan and health. But the translation to humans requires care. The takeaway is not that everyone should follow one rigid fasting window. The takeaway is that timing is biology — and maintaining rhythm may be one underappreciated part of resilience, recovery, and healthy aging.Chapters00:00 Can Meal Timing Slow Aging?02:16 Introduction from the Systems Aging GRC03:08 What Are Circadian Rhythms?03:46 Shift Work, Jet Lag, and Health Risk04:30 Circadian Disruption and Cancer Risk04:59 Time-Restricted Eating vs Intermittent Fasting05:29 Eating Windows and Overnight Fasting06:20 Why Fruit Flies Are Powerful Aging Models07:17 The “Keep Me Young” Genes<a href="https://www.youtube.com/watch?v=vAizRfbYLjc
- Jun 29, 202631 min
Dr. Rich Miller: “There Are No Biomarkers of Aging”
🧠 Episode OverviewWhat if “biological age” as a single number is the wrong way to think about aging?In this episode of The ReProgram, Dr. George Murphy sits down with Dr. Rich Miller at the Gordon Research Conference Systems Aging Meeting in Maine.Dr. Miller is a Professor of Pathology at the University of Michigan and one of the leaders of the Interventions Testing Program, the gold standard for testing longevity interventions in genetically diverse mice.This conversation challenges some of the biggest assumptions in longevity science: biomarkers of aging, cellular senescence, the search for one cause of aging, and the idea that mouse lifespan results automatically translate into human recommendations.The central message:Aging is not one pathway, one biomarker, or one number.The real question is not simply what causes aging.The real question is what can postpone many forms of age-related decline at the same time.🔑 KeywordsRichard Miller, Interventions Testing Program, ITP, aging biology, longevity science, geroscience, biological age, biomarkers of aging, aging-rate indicators, anti-aging drugs, geroprotectors, rapamycin, acarbose, ergothioneine🧠 Takeaways• Aging should not be reduced to one cause, one pathway, one biomarker, or one biological age number.• Rich Miller argues that the key question is not what causes aging, but what postpones many forms of age-related damage at once.• Lifespan is useful because it is definitive, but a true anti-aging drug should also delay multiple forms of functional decline.• Most proposed longevity interventions fail when tested rigorously.• Biomarkers of aging and aging-rate indicators are not the same thing.• A biomarker may change with age. An aging-rate indicator should tell us whether aging is moving faster or slower.• “Biological age” as a single number may hide important differences across tissues, systems, and disease risks.• Ergothioneine is intriguing in slow-aging mice, but it is not yet clear whether it is causal or simply a marker of a broader metabolic state.• Sex differences matter. Some interventions work in male mice but not female mice.• Rapamycin and acarbose are exciting in mice, but they are not proven human longevity drugs.• No drug has yet been proven to extend human lifespan by slowing aging itself.🎙️ The ReProgram PerspectiveThe ReProgram lens is simple:Mechanism over marketing.Outcomes over biomarkers.Trade-offs over hype.This episode is a reminder that longevity science needs both ambition and restraint.A compound that changes a biomarker has not necessarily slowed aging.A drug that extends lifespan in mice is not automatically safe or effective for humans.And a single “biological age” number may not capture the complexity of how real people age.Rich Miller’s message is not that aging biology is impossible.It is that the field has to be precise about what the data actually prove.The future of longevity science depends on rigorous testing, better endpoints, genetic diversity, sex-specific biology, and a clear distinction between promising mechanisms and proven outcomes.Chapters00:00 Are There Really Biomarkers of Aging?02:09 Dr. Rich Miller’s Origin Story03:24 How His Views on Aging Changed04:21 How Rich Miller Defines Aging and Its Complexities05:48 The Interventions Testing Program (ITP)07:31 What Is a True Anti-Aging Drug?08:37 Longevity Signatures and Metabolites10:33 The Role of Ergothionine in Aging13:17 Biomarkers vs Aging-Rate Indicators16:26 Sex Differences in Aging Research19:11 The Importance of Genetically Diverse Models22:09 Advocating for Aging Research23:45 Aging Research and Cancer25:19 Disease Silos in Science27:11 Rich Miller’s Own Longevity Habits29:51 The Risk of Rapamycin Self-ExperimentationNotesThe Interventions Testing Program (ITP): https://www.nia.nih.gov/research/dab/interventions-testing-program-itpDr. Rich Miller Lab: https://www.richmillerlab.com/
- Jun 15, 202625 min
GLP-1 Agonists and Longevity: The First ReProgram Scorecard
🧠 Episode OverviewAre GLP-1 agonists longevity drugs?Not weight loss drugs.Not cosmetic drugs.Not simply appetite drugs.In this episode of The ReProgram, Dr. George Murphy launches a new recurring format: The ReProgram Scorecard — a science-first framework for grading popular longevity interventions through the same lens every time:Mechanistic plausibility.Human evidence.Magnitude of likely benefit.Safety and downside risk.Who may benefit most.Who should be cautious.Cost and accessibility.Longevity hype risk.And the final ReProgram grade.🔑 KeywordsGLP-1 agonists, GLP-1 and longevity, semaglutide, Ozempic, tirzepatide, metabolic health, healthspan, aging biology, inflammation, brain aging, cognitive decline, neuroinflammation, neuronal resilience, longevity medicine, geroscience, The ReProgram Podcast, Dr. George Murphy.🧠 Takeaways• GLP-1 agonists should not be understood only as weight-loss drugs. • GLP-1 agonists are not yet proven to slow biological aging, extend lifespan, reverse aging clocks, prevent frailty, or broadly preserve function across all older adults.• The magnitude of likely benefit is highly context-dependent. People with obesity, insulin resistance, type 2 diabetes, cardiovascular risk, fatty liver disease, metabolic syndrome, or inflammation linked to metabolic dysfunction may benefit most.• For metabolically healthy people using GLP-1 agonists purely as longevity hacks, the benefit is much less clear.• Safety matters. These are real drugs with real side effects, and they should not be treated as casual wellness supplements.• Lean mass preservation is critical. Weight loss without attention to resistance training, protein intake, and muscle maintenance may undermine long-term resilience, especially in older adults.🎙️ The ReProgram PerspectiveThe ReProgram lens is clear:Mechanism over marketing.Evidence over anecdotes.Trade-offs over hype.GLP-1 agonists are not magic. They are not proven anti-aging drugs. And they should not be marketed as universal longevity tools. But they also should not be dismissed as simple weight-loss drugs.📊 The ReProgram ScorecardMechanistic plausibility: 4.5 / 5Strong aging-relevant biology: metabolism, inflammation, cardiovascular risk, immune tone, and potentially neuronal resilience.Human evidence: 3.5 / 5 Strong for cardiometabolic outcomes. Promising but incomplete for longevity, resilience, and cognitive decline.Magnitude of likely benefit:4 / 5 in high-risk metabolic populations. 2.5–3 / 5 for broad longevity use.Safety and downside risk: 3 / 5 Useful drugs, but real side effects, medical supervision required, and muscle preservation matters.Who may benefit most: People with obesity, type 2 diabetes, insulin resistance, cardiovascular risk, fatty liver disease, metabolic syndrome, or inflammation linked to metabolic dysfunction.Who should be cautious: People with low muscle mass, frailty, eating disorders, certain GI or pancreatic/gallbladder risks, pregnancy considerations, relevant endocrine cancer risks, or anyone using unregulated versions.Cost and accessibility: 2 / 5 Major barrier.Longevity hype risk: High The biology is real, but the public narrative is ahead of the evidence.Final ReProgram Grade: B+Chapters00:00 Are GLP-1 Agonists Longevity Drugs?01:03 Introducing The ReProgram Scorecard02:02 What Are GLP-1 and Incretin-Based Therapies?03:33 Mechanistic Plausibility: Why GLP-1 Biology Matters for Aging06:27 Human Evidence: Cardiometabolic Healthspan vs. Longevity Proof08:45 Magnitude of Benefit: Who Has the Most Room to Improve?10:52 Safety, Side Effects, and Lean Mass Concerns14:04 Identifying Who May Benefit Most
- Jun 1, 202621 min
Can AI Decode Human Aging?
ReProgram Episode 14AI and Longevity: Hype, Hope, and the Biology of Aging🧠 Episode OverviewWhat if your doctor could look at your bloodwork, medical history, genome, proteins, metabolites, microbiome, and health trajectory - and tell you more than whether you are sick today?Can artificial intelligence decode human aging?AI will not magically cure aging. It will not replace biology. And it will not tell us exactly how to live forever.But it may help us do something incredibly important:See patterns in human aging that are too complex for the human mind to detect alone.In this episode of The ReProgram, Dr. George Murphy explores the real promise of AI in longevity science — and where the hype goes wrong.Aging is not one gene, one pathway, one biomarker, or one supplement. Aging is a moving, interacting network across time.That is why AI matters.But prediction is not understanding.A biomarker is not an outcome.And an AI-generated recommendation is not automatically personalized medicine.The future is not AI instead of biology.It is AI plus biology.🧠 Takeaways• AI will not magically cure aging, but it may become one of the most powerful tools for organizing biological complexity.• Aging is not a single pathway, gene, biomarker, or intervention. It is a dynamic network that changes over time.• The most useful question is not simply whether AI can predict aging, but whether AI can help us understand, measure, and eventually preserve resilience.• AI can identify patterns across massive datasets, but pattern recognition is not the same as biological truth.• Prediction is not understanding. An AI model may predict risk without explaining the mechanism behind that risk.• Bad data plus powerful AI does not create truth. It creates confident noise.• AI-generated health recommendations are not automatically personalized medicine; they may be personalized guesses delivered with confidence.• The future of longevity science is not AI instead of biology. It is AI plus biology.• The winning formula is: AI plus longitudinal human data plus functional biology plus clinical outcomes.🎙️ The ReProgram PerspectiveThe ReProgram lens is clear:AI is a tool.Biology is the reality.Health is the outcome.AI should not be dismissed as hype, because it is already changing scientific work. It is being used in data analysis, bioinformatics, coding, experimental design, literature review, hypothesis generation, logic checking, and the interpretation of large-scale biological datasets.But AI should also not be treated as magic.In longevity science, a correlation is not enough. A biomarker can correlate with age and still not drive aging. A biological age number can move after an intervention and still not prove that healthspan improved. A predictive model can sound authoritative and still fail to explain what is happening biologically.That is why this episode argues for grounded optimism.Be excited about AI.Be skeptical of overclaims.Demand validation.Ask whether predictions connect to mechanisms.Ask whether mechanisms connect to outcomes.Ask whether outcomes improve human lives.The future is not AI replacing biology.The future is AI helping us ask better biological questions — and then testing those questions in the lab and the clinic.Office Artifact:On the desk: GATTACA on DVD; 1997; IMDb7.7Chapters00:00 The Promise of AI in Longevity02:02 Why AI and Longevity are Both Exciting and Overhyped03:36 AI in the Lab, Not Science Fiction05:01 Aging is a Network That Changes Over Time06:35 Patterns in Aging and AIs Role09:11 Understanding Mechanisms Behind Predictions12:04 AI + Experimentation = Success14:37 The Hype vs. Reality of AI in Longevity17:18 The Future of AI in Longevity Medicine18:54 Personalizing Longevity with AI21:07 The Future: AI and Human Biology Connection
- May 18, 202622 min
NAD and Aging: Did We Get the Story Wrong
ReProgram Episode 14The NAD Myth? What the New Human Data Really Say🧠 Episode OverviewIn this episode of The ReProgram, Dr. George Murphy takes a critical but balanced look at one of the most popular ideas in the longevity space:That NAD levels decline with age — and that boosting NAD may help slow aging.But new human data challenge one of the most common assumptions behind the NAD story:Whole-blood NAD levels may not decline with age.This episode explores what that finding means — and what it does not mean.The central takeaway:NAD is not dead.But the simplistic NAD longevity story needs a reset.🔑 KeywordsNAD, NAD+, aging, longevity, NR, NMN, NAD boosters, nicotinamide riboside, nicotinamide mononucleotide, mitochondrial function, DNA repair, sirtuins, PARPs, CD38, cellular metabolism, biological aging, healthspan, resilience, recovery capacity, inflammation, stress response, biomarker, whole-blood NAD, NAD decline, NAD supplements, NAD IV therapy, metabolism, cellular stress, anti-aging supplements, longevity science, The ReProgram Podcast🧠 Takeaways• NAD is essential biology, but it should not be treated as a magic anti-aging molecule.• New human data challenge the idea that whole-blood NAD levels universally decline with age.• Raising blood NAD is not the same thing as proving that aging has slowed.• NAD biology is likely tissue-specific, disease-specific, stress-specific, and context-dependent.• Blood NAD is not necessarily a reliable window into NAD metabolism in muscle, brain, liver, immune cells, or other tissues.• NAD boosters like NR and NMN can raise NAD-related metabolites, but that does not automatically mean they improve healthspan or longevity.• The most honest current framing is that NAD boosters are biologically plausible, biomarker-active, and clinically unproven as general longevity therapies.• NAD may be more relevant in specific contexts of stress, disease, frailty, metabolic dysfunction, or impaired recovery than as a universal supplement for healthy people.• NAD infusions and high-cost wellness protocols deserve extra skepticism because the marketing often exceeds the evidence.• Longevity interventions should be judged by function, resilience, healthspan, and clinical outcomes — not by biomarker movement alone.🎙️ The ReProgram PerspectiveNAD biology matters, but the public story has become too simple.The key question is not whether we can raise NAD. The key question is whether doing so improves function, resilience, recovery, disease risk, or healthspan.Blood biomarkers can be useful, but they are not outcomes. Aging biology is not a supplement slogan.The ReProgram lens is clear: mechanism over marketing, outcome data over anecdotes, and trade-offs over hype.Chapters00:00 The NAD Longevity Story Just Changed01:24 What NAD Is and Why It Matters03:31 NAD as Cellular Currency04:37 The Old Model: Aging, Inflammation, and NAD Decline06:32 The New Human Data on Whole-Blood NAD08:30 Why Blood NAD Is Not the Whole Story11:01 NAD Boosters: What They May Actually Do12:58 NAD Boosters remain Scientifically Interesting14:39 NAD Boosters: Limitations16:55 Should You Take NAD for Longevity?19:28 The ReProgram Takeaway: NAD Is Not Dead, But the Hype Needs a ResetNotes: Nature Metabolism Paper: Human whole-blood NAD+ levels do not vary with age or lifestyle interventions: https://www.nature.com/articles/s42255-026-01537-5Cell Metabolism Paper: NAD depletion in skeletal muscle does not compromise muscle function or accelerate aging: https://www.cell.com/cell-metabolism/fulltext/S1550-4131(25)00212-8
- May 4, 202644 min
Measuring and Modifying Biological Age: What the Science Actually Shows
ReProgram Episode 13🧠 Episode OverviewWhat does it actually mean to measure your biological age—and can it be changed? In this episode of The ReProgram, Dr. George Murphy sits down with Dr. Jesse Poganik, a leading scientist in the field of biological aging clocks and biomarkers of aging. Together, they unpack the science behind biological age—how it’s measured, what it reflects, and whether it represents a causal driver of aging or simply a readout of deeper biological processes. This conversation goes beyond the hype. It explores the emerging tools used to quantify aging, the limitations of current approaches, and what it will take to translate these measurements into meaningful clinical interventions. From organ transplantation to immune system signaling, Dr. Poganik shares how real-world biological systems are helping decode the mechanisms that shape how we age.🔑 Keywordsbiological age, epigenetic clocks, aging biomarkers, DNA methylation, longevity science, healthspan, resilience, systems biology, immune aging, biomarkers of aging, translational medicine, aging mechanisms, clinical biomarkers, longevity interventions🔬 What You’ll Learn• What “biological age” actually measures—and what it doesn’t • How epigenetic clocks are built and why they’ve gained traction • The difference between correlation and causation in aging biomarkers • Why systemic signals (like blood and immune factors) may regulate aging • How organ transplantation provides a natural experiment in aging biology • The biggest challenges in bringing biological age testing into the clinic • What standardization efforts (like the Biomarkers of Aging Consortium) aim to solve • Whether modifying biological age is currently possible—and what’s coming next 🎙️ The ReProgram PerspectiveBiological age is not just a number to optimize.It is a signal—one that reflects deeper biological processes we are only beginning to understand.The challenge is not simply to measure aging more precisely. The challenge is to determine whether those measurements represent something we can actually change.Because longevity is not about chasing metrics.It is about understanding the biology those metrics reflect and ultimately, learning how to influence it.🎧 Final ThoughtWe can now measure aging with increasing precision.But the real question remains:Are we measuring something we can change—or something we still don’t fully understand?Office Artifact: On the desk: Steampunk Pocket WatchChapters00:00:00 Introduction to Measuring and Modifying Biological Age00:04:07 Defining Biological Age00:04:03 Epigenetic Clocks and Their Role in the Evolution of the Field00:10:02 Causality in Aging Biomarkers00:12:47 Clinical Applications of Biological Age00:16:08 Nutritional Interventions and Biological Age00:19:00 Understanding Aging Signatures00:21:35 Transient Changes in Biological Age00:24:27 Heterochronic Transplantation Studies00:27:26 Blood as the Conduit of Aging or Rejuvenation Factors00:30:25 Longitudinal Data in Organ Transplantation00:33:23 The Biomarkers of Aging Consortium00:36:25 The Birth of the Biomarkers of Aging Consortium00:40:06 Personal Reflections on Aging and Longevity00:41:47 Wrap Up and Putting It All TogetherNotes: Jesse Poganik, PhD: https://www.poganik.com/Biomarkers of Aging Consortium: https://www.agingconsortium.org/The inaugural collaborative manuscript of the Biomarkers of Aging Consortium was published in Cell: https://www.cell.com/cell/fulltext/S0092-8674(23)00857-7Landmark Horvath Biological Age Paper: https://pubmed.ncbi.nlm.nih.gov/24138928/Clinical Trials Using Biomarkers of Aging: CALERIE: https://clinicaltrials.gov/study/NCT00427193DO-HEALTH: https://do-health.eu/about/trial/COSMOS Multivitamin Trial: https://cosmostrial.org/
About The ReProgram
The ReProgram is dedicated to exploring how we can extend the healthy human lifespan through science and self-understanding. Hosted by Dr. George Murphy, each episode dives into the rapidly evolving fields of aging biology, longevity, regenerative medicine, and geroscience.From cellular rejuvenation and advanced therapeutics to lifestyle strategies that build resilience against disease, we examine what the science actually shows—and what it doesn’t. No hype. No myths. Just rigorous, evidence-based conversations about how we can reprogram our biology to live longer and healthier lives.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from The ReProgram in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's The ReProgram daily summary?
It's a free AI-powered email that summarizes new episodes of The ReProgram as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the The ReProgram podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official The ReProgram product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Dr. George Murphy.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does The ReProgram release new episodes?
The ReProgram publishes biweekly. Our AI generates a summary within hours of each new episode.
What topics does The ReProgram cover?
The ReProgram covers topics including Science, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting The ReProgram summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.